897
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Postsurgical neuropathic pain: lidocaine 700 mg medicated plaster or oral treatments in clinical practice

ORCID Icon, , , ORCID Icon & ORCID Icon
Pages 725-735 | Received 04 May 2022, Accepted 01 Jun 2022, Published online: 17 Jun 2022

Figures & data

Table 1. Baseline characteristics of all patients with postsurgical neuropathic pain.

Figure 1. Oral recommended first-line medications documented for the treatment of postsurgical neuropathic pain in the OM group after switch from previous medication (n = 531).

OM: Oral first-line medication; SSNRI: Selective serotonin-norepinephrine reuptake inhibitor.

Figure 1. Oral recommended first-line medications documented for the treatment of postsurgical neuropathic pain in the OM group after switch from previous medication (n = 531).OM: Oral first-line medication; SSNRI: Selective serotonin-norepinephrine reuptake inhibitor.
Figure 2. Change in concomitant medication and in rescue medication over the 24-week observation period.

Data for nonopioids and mild opioids are not shown.

LMP: Lidocaine 700 mg medicated plaster; OM: Oral medication.

Figure 2. Change in concomitant medication and in rescue medication over the 24-week observation period.Data for nonopioids and mild opioids are not shown.LMP: Lidocaine 700 mg medicated plaster; OM: Oral medication.
Figure 3. Average 24-h pain intensity index.

(A) Change from baseline over the observation period. (B) Improvement versus baseline at end of observation.

PIX: Pain intensity index.

Figure 3. Average 24-h pain intensity index. (A) Change from baseline over the observation period. (B) Improvement versus baseline at end of observation.PIX: Pain intensity index.
Figure 4. Overall quality of life.

Change in physical component score over the observation period.

Figure 4. Overall quality of life.Change in physical component score over the observation period.

Table 2. Outcome of further effectiveness parameters at the end of observation.

Figure 5. Drug-related adverse events over the observation period.
Figure 5. Drug-related adverse events over the observation period.

Table 3. All drug-related adverse events reported in patients receiving lidocaine 700 mg medicated plaster during the observation period (n = 531).

Table 4. Main drug-related adverse events reported in patients receiving oral first-line medication during the observation period (n = 531).